由买买提看人间百态

boards

本页内容为未名空间相应帖子的节选和存档,一周内的贴子最多显示50字,超过一周显示500字 访问原贴
Stock版 - 九月17号四个IPO
相关主题
今天6只ipo,买哪个好呢?关于FB的一则濡沫
CIVI todayPark大牛, CHK该怎么办?
哈哈哈哈 TKAIFB被苦主们告了
分析师开始升级中丐股了。请教关于underwriter的解释
一时冲动,26.25 买了CYOU今天两个IPO都很衰prqr和fomx
告诉你们什么是MM庄家就是想要FB暴跌啊,小散们跟着乐呵什么?
How Wall Street predicts for 2016 stock marketRBIO IPO 值得入吗
花姐分析师全都是马后炮猜一下明天TKAI的顶在哪里?5个包子奖励
相关话题的讨论汇总
话题: company话题: nasdaq话题: phase话题: shares
进入Stock版参与讨论
1 (共1页)
O****N
发帖数: 1458
1
【 以下文字转载自 xiaoyaogu 俱乐部 】
发信人: OKMSDN (假作真时真亦假), 信区: xiaoyaogu
标 题: 九月17号四个IPO
发信站: BBS 未名空间站 (Mon Sep 15 22:34:45 2014, 美东)
Wednesday, September 17
Home health and human services provider, Civitas Solutions (NYSE: CIVI),
serves handicapped individuals who are intellectually, behaviorally, or
physically challenged. The company focuses on providing quality programs
that are also cost effective.
As of June 30, the company had nearly 30,000 clients being served by a
workforce of 20,000. Underwriters Barclays, Merrill Lynch and UBS expect to
sell 11.7 million shares for $20 to $23 per share.
ProQR (NASDAQ: PRQR), on the other hand, is “born from the dream to beat
cystic fibrosis in one child,” according to its S-1. The company’s RNA-
based treatment is designed for use with patients suffering from cystic
fibrosis. There is also believe the treatment may address other genetic
disorders caused by single protein genetic mutation.
Underwriters Leerink Partners and Deutsche Bank expect to price 6.25 million
shares between $11 and $13 apiece.
rEVO Biologics (NASDAQ: RBIO) specializes in developing and commercializing
drugs for patients with rare, life-threatening conditions. To date, the
company has one commercial product, A Tryn, that is used to prevent blood
clots in surgery and childbirth. Despite a 19-percent increase in revenue
from 2012 to 2013, the company still faces substantial losses because of R&D
and costs associated with the product.
Piper Jaffray and Guggenheim lead the underwriting effort and expect to
price 3.6 million shares between $13 and $15.
Tokai Pharma (NASDAQ: TKAI) develops proprietary treatments for prostate
cancer. Its lead drug, Galeterone, has been tested on 250 patients in Phase
1 and Phase 2 clinical trials. Phase 3 is currently being finalized and the
company expects to get results from the FDA in the first half of 2015.
Underwriters for the offering are BMO Capital, William Blair and Stifel.
They expect to sell 5.4 million shares for $13 to $15 each.
看看明天谁发财
m******e
发帖数: 1399
2
小药股一般都没戏。

★ 发自iPhone App: ChineseWeb 7.3

【在 O****N 的大作中提到】
: 【 以下文字转载自 xiaoyaogu 俱乐部 】
: 发信人: OKMSDN (假作真时真亦假), 信区: xiaoyaogu
: 标 题: 九月17号四个IPO
: 发信站: BBS 未名空间站 (Mon Sep 15 22:34:45 2014, 美东)
: Wednesday, September 17
: Home health and human services provider, Civitas Solutions (NYSE: CIVI),
: serves handicapped individuals who are intellectually, behaviorally, or
: physically challenged. The company focuses on providing quality programs
: that are also cost effective.
: As of June 30, the company had nearly 30,000 clients being served by a

s*****i
发帖数: 1781
3
查下nasdaq的ipo没说明天有上市啊
1 (共1页)
进入Stock版参与讨论
相关主题
猜一下明天TKAI的顶在哪里?5个包子奖励一时冲动,26.25 买了CYOU
TKAI 未来会怎样,还有前途吗?告诉你们什么是MM
tkai 要割吗 27 入的How Wall Street predicts for 2016 stock market
TKAI很快就去个位数了.花姐分析师全都是马后炮
今天6只ipo,买哪个好呢?关于FB的一则濡沫
CIVI todayPark大牛, CHK该怎么办?
哈哈哈哈 TKAIFB被苦主们告了
分析师开始升级中丐股了。请教关于underwriter的解释
相关话题的讨论汇总
话题: company话题: nasdaq话题: phase话题: shares